Dermatology Medical News about mycosis fungoides, bexarotene, UVB-NB

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB
Journal of Dermatological Treatment , 07/23/09

D'Acunto C et al. - In a case study of mycosis fungoides (MF) unresponsive to conventional therapy, subsequently treated with bexarotene and narrow-band ultraviolet B (UVB-NB), it appears that the combined therapy UVB-NB and bexarotene may be considered as an alternative treatment to psoralen and ultraviolet A (PUVA) and bexarotene.

Methods

MF is the most common form of cutaneous T-cell lymphoma (CTCL), a non-Hodgkin lymphoma characterized by proliferation of atypical epidermotrophic helper/memory T cells in the skin.
Therapeutic management includes topical therapy such as topical corticosteroids, topical chemotherapy or phototherapy; or systemic therapy such as PUVA, extracorporeal phototherapy, radiation, and mono or polychemotherapy.

Results

Bexarotene belongs to a new subclass of retinoids, binding primarily the nuclear hormone receptors RXRs.
Bexarotene has the same effect as its natural counterpart: 9-cis-retinoic acid.
Bexarotene may be used alone or in association with interferon alfa, interferon gamma, extracorporeal photophoresis and PUVA.
75 mg/day of bexarotene associated with 0.3 J/cm2 UVB-NB was used as an initial dose.
After 8 wks, clinical lesions markedly improved without recording hypercholesterolemia or hypothyroidism.
During follow-up, no relapses were detected.

<< Previous
Cutaneous melanoma - atypical variants and presentations

Next >>
Dermal Hyaluronan Is Rapidly Reduced by Topical Treatment with...

Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sezary syndrome
Journal of Cutaneous Pathology, 11/06/09 Relevance Score: 66%

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
Annals of Oncology, 11/16/09 Relevance Score: 64%

Cerebral mycosis: 7-year retrospective series in a tertiary center
Neuropathology, 11/03/09 Relevance Score: 64%

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
Journal of Clinical Oncology, 10/20/09 Relevance Score: 64%

A practical approach to using methotrexate
Dermatology in Practice, 10/14/09 Relevance Score: 62%